Report Content

Chapter 1   Methodology & Scope

1.1    Definition and forecast parameters

1.1.1    Definitions

1.1.2    Methodology and forecast parameters

1.2    Data sources

1.2.1    Secondary

1.2.2    Primary

Chapter 2   Executive Summary

2.1    North America esoteric testing industry summary, 2017 - 2028

2.1.1    Country trends

2.1.2    Test type trends

2.1.3    Technology trends

Chapter 3   North America Esoteric Testing Market Analysis

3.1    Industry segmentation

3.2    Industry landscape, 2017 - 2028 (USD Million)

3.3    Major factor analysis

3.3.1    Drivers

3.3.1.1   Technological advancements in esoteric testing

3.3.1.2   Rising occurrence of complex and rare medical disorders in the U.S

3.3.1.3   Increasing prevalence of cancer and infectious diseases

3.3.1.4   Growing demand for genomics and proteomics

3.3.1.5   Rising awareness for early disease detection

3.3.2    Industry pitfalls and challenges

3.3.2.1   Stringent regulatory framework

3.4    Analysis of COVID-19 impact on the industry

3.5    Porter’s analysis

3.6    Competition review, 2021

3.7    PEST analysis

Chapter 4   North America Esoteric Testing Market, By Test Type

4.1    Market trends

4.2    Endocrinology

4.2.1    Market estimates and forecast, by country, 2017 - 2028 (USD Million)

4.3    Infectious disease & immunology

4.3.1    Market estimates and forecast, by country, 2017 - 2028 (USD Million)

4.4    Oncology

4.4.1    Market estimates and forecast, by country, 2017 - 2028 (USD Million)

4.5    Toxicology

4.5.1    Market estimates and forecast, by country, 2017 - 2028 (USD Million)

4.6    Neurology

4.6.1    Market estimates and forecast, by country, 2017 - 2028 (USD Million)

4.7    Genomics

4.7.1    Market estimates and forecast, by country, 2017 - 2028 (USD Million)

4.8    Others

4.8.1    Market estimates and forecast, by country, 2017 - 2028 (USD Million)

Chapter 5   North America Esoteric Testing Market, By Technology

5.1    Market trends

5.2    Mass spectrometry

5.2.1    Market estimates and forecast, by country, 2017 - 2028 (USD Million)

5.3    Flow cytometry

5.3.1    Market estimates and forecast, by country, 2017 - 2028 (USD Million)

5.4    ELISA

5.4.1    Market estimates and forecast, by country, 2017 - 2028 (USD Million)

5.5    Radioimmunoassay

5.5.1    Market estimates and forecast, by country, 2017 - 2028 (USD Million)

5.6    Chemiluminescence

5.6.1    Market estimates and forecast, by country, 2017 - 2028 (USD Million)

5.7    RT-PCR

5.7.1    Market estimates and forecast, by country, 2017 - 2028 (USD Million)

5.8    Others

5.8.1    Market estimates and forecast, by country, 2017 - 2028 (USD Million)

Chapter 6   North America Esoteric Testing Market, By Country

6.1    Market trends

6.2    U.S.

6.2.1    Market size by test type, 2017 - 2028 (USD Million)

6.2.2    Market size by technology, 2017 - 2028 (USD Million)

6.3    Canada

6.3.1    Market size by test type, 2017 - 2028 (USD Million)

6.3.2    Market size by technology, 2017 - 2028 (USD Million)

Chapter 7   Company Profiles

7.1    ACM Global Laboratories

7.1.1    Business overview

7.1.2    Financial data

7.1.3    Product landscape

7.1.4    Strategic outlook

7.2    American Esoteric Laboratories (Sonic Healthcare Limited)

7.2.1    Business overview

7.2.2    Financial data

7.2.3    Product landscape

7.2.4    Strategic outlook

7.3    Arup Laboratories

7.3.1    Business overview

7.3.2    Financial data

7.3.3    Product landscape

7.3.4    Strategic outlook

7.4    BioMONTR

7.4.1    Business overview

7.4.2    Financial data

7.4.3    Product landscape

7.4.4    Strategic outlook

7.5    Fulgent Genetics Inc.

7.5.1    Business overview

7.5.2    Financial data

7.5.3    Product landscape

7.5.4    Strategic outlook

7.6    Genomic Health

7.6.1    Business overview

7.6.2    Financial data

7.6.3    Product landscape

7.6.4    Strategic outlook

7.7    Invitae Corporation

7.7.1    Business overview

7.7.2    Financial data

7.7.3    Product landscape

7.7.4    Strategic outlook

7.8    Laboratory Corporation of America

7.8.1    Business overview

7.8.2    Financial data

7.8.3    Product landscape

7.8.4    Strategic outlook

7.9    Mayo Medical Laboratories

7.9.1    Business overview

7.9.2    Financial data

7.9.3    Product landscape

7.9.4    Strategic outlook

7.10    Miraca Holdings Inc.

7.10.1    Business overview

7.10.2    Financial data

7.10.3    Product landscape

7.10.4    Strategic outlook

7.11    Myriad Genetics, Inc.

7.11.1    Business overview

7.11.2    Financial data

7.11.3    Product landscape

7.11.4    Strategic outlook

7.12    Nordic Laboratories

7.12.1    Business overview

7.12.2    Financial data

7.12.3    Product landscape

7.12.4    Strategic outlook

7.13    OPKO Health Inc.

7.13.1    Business overview

7.13.2    Financial data

7.13.3    Product landscape

7.13.4    Strategic outlook

7.14    Quest Diagnostics, Inc.

7.14.1    Business overview

7.14.2    Financial data

7.14.3    Product landscape

7.14.4    Strategic outlook